In Vitro Antifungal Susceptibilities of Uncommon Basidiomycetous Yeasts

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2004 Jun 25

PMID 15215135

Citations 6

Authors

Carolina Serena

Francisco Javier Pastor

Montserrat Ortoneda

Javier Capilla

Nicole Nolard

Josep Guarro

Affiliations

Soon will be listed here.

Abstract

The in vitro activities of eight antifungal drugs against 50 isolates of basidiomycetous yeasts were determined by a microdilution method. In general fluconazole and micafungin were inactive. Terbinafine was active only against Sporobolomyces salmonicolor. The activities of the other antifungals were variable and depended on the species tested. The new triazoles showed the lowest MICs, but amphotericin B and itraconazole were the only drugs active against Cryptococcus albidus.

Citing Articles

Case Report of Cryptococcus Albidus Peritonitis in a Peritoneal Dialysis Patient and a Review of the Literature.

Ragupathi L, Reyna M Perit Dial Int. 2014; 35(4):421-7.

PMID: 24584615 PMC: 4520724. DOI: 10.3747/pdi.2013.00134.

Cryptococcus laurentii biofilms: structure, development and antifungal drug resistance.

Ajesh K, Sreejith K Mycopathologia. 2012; 174(5-6):409-19.

PMID: 22936102 DOI: 10.1007/s11046-012-9575-2.

Identification of medically important Candida and non-Candida yeast species by an oligonucleotide array.

Leaw S, Chang H, Barton R, Bouchara J, Chang T J Clin Microbiol. 2007; 45(7):2220-9.

PMID: 17507521 PMC: 1933000. DOI: 10.1128/JCM.00543-07.

Efficacy of voriconazole in a guinea pig model of invasive trichosporonosis.

Serena C, Gilgado F, Marine M, Pastor F, Guarro J Antimicrob Agents Chemother. 2006; 50(6):2240-3.

PMID: 16723595 PMC: 1479129. DOI: 10.1128/AAC.00045-06.

In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus.

Serena C, Fernandez-Torres B, Pastor F, Trilles L, Lazera M, Nolard N Antimicrob Agents Chemother. 2005; 49(7):2994-6.

PMID: 15980382 PMC: 1168639. DOI: 10.1128/AAC.49.7.2994-2996.2005.

References

Kordossis T, Avlami A, Velegraki A, Stefanou I, Georgakopoulos G, Papalambrou C . First report of Cryptococcus laurentii meningitis and a fatal case of Cryptococcus albidus cryptococcaemia in AIDS patients. Med Mycol. 1999; 36(5):335-9. View

Johnson L, Bradley S, Kauffman C . Fungaemia due to Cryptococcus laurentii and a review of non-neoformans cryptococcaemia. Mycoses. 1998; 41(7-8):277-80. DOI: 10.1111/j.1439-0507.1998.tb00338.x. View

Galan-Sanchez F, Garcia-Martos P, Rodriguez-Ramos C, Marin-Casanova P, Mira-Gutierrez J . Microbiological characteristics and susceptibility patterns of strains of Rhodotorula isolated from clinical samples. Mycopathologia. 2000; 145(3):109-12. DOI: 10.1023/a:1007059005753. View

Kovacicova G, Lovaszova M, Hanzen J, Roidova A, Mateicka F, Lesay M . Persistent fungemia--risk factors and outcome in 40 episodes. J Chemother. 2001; 13(4):429-33. DOI: 10.1179/joc.2001.13.4.429. View

Fournier S, Pavageau W, Feuillhade M, Deplus S, Zagdanski A, Verola O . Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia. Eur J Clin Microbiol Infect Dis. 2003; 21(12):892-6. DOI: 10.1007/s10096-002-0841-y. View

Jessup C, Ryder N, Ghannoum M . An evaluation of the in vitro activity of terbinafine. Med Mycol. 2000; 38(2):155-9. DOI: 10.1080/mmy.38.2.155.159. View

Zaas A, Boyce M, Schell W, Lodge B, Miller J, Perfect J . Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates. J Clin Microbiol. 2003; 41(11):5233-5. PMC: 262498. DOI: 10.1128/JCM.41.11.5233-5235.2003. View

Arikan S, Hascelik G . Comparison of NCCLS microdilution method and Etest in antifungal susceptibility testing of clinical Trichosporon asahii isolates. Diagn Microbiol Infect Dis. 2002; 43(2):107-11. DOI: 10.1016/s0732-8893(02)00376-0. View

Wolf D, Falk R, Hacham M, Theelen B, Boekhout T, Scorzetti G . Multidrug-resistant Trichosporon asahii infection of nongranulocytopenic patients in three intensive care units. J Clin Microbiol. 2001; 39(12):4420-5. PMC: 88559. DOI: 10.1128/JCM.39.12.4420-4425.2001. View

10.

Wildfeuer A, Seidl H, Paule I, Haberreiter A . In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses. 1998; 41(7-8):309-19. DOI: 10.1111/j.1439-0507.1998.tb00344.x. View

11.

Cawley M, Braxton G, Haith L, Reilly K, Guilday R, Patton M . Trichosporon beigelii infection: experience in a regional burn center. Burns. 2000; 26(5):483-6. DOI: 10.1016/s0305-4179(99)00181-3. View

12.

Tawara S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N . In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother. 1999; 44(1):57-62. PMC: 89628. DOI: 10.1128/AAC.44.1.57-62.2000. View

13.

Moretti-Branchini M, Fukushima K, Schreiber A, Nishimura K, Papaiordanou P, Trabasso P . Trichosporon species infection in bone marrow transplanted patients. Diagn Microbiol Infect Dis. 2001; 39(3):161-4. DOI: 10.1016/s0732-8893(01)00215-2. View

14.

KURTZ M, Heath I, Marrinan J, Dreikorn S, Onishi J, Douglas C . Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother. 1994; 38(7):1480-9. PMC: 284580. DOI: 10.1128/AAC.38.7.1480. View

15.

Groll A, Walsh T . Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect. 2001; 7 Suppl 2:8-24. DOI: 10.1111/j.1469-0691.2001.tb00005.x. View

16.

Anatoliotaki M, Mantadakis E, Galanakis E, Samonis G . Rhodotorula species fungemia: a threat to the immunocompromised host. Clin Lab. 2003; 49(1-2):49-55. View

17.

Paphitou N, Ostrosky-Zeichner L, Paetznick V, Rodriguez J, Chen E, Rex J . In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother. 2002; 46(4):1144-6. PMC: 127118. DOI: 10.1128/AAC.46.4.1144-1146.2002. View

18.

Plazas J, Portilla J, Boix V, Perez-Mateo M . Sporobolomyces salmonicolor lymphadenitis in an AIDS patient. Pathogen or passenger?. AIDS. 1994; 8(3):387-8. DOI: 10.1097/00002030-199403000-00015. View

19.

Espinel-Ingroff A . In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol. 1998; 36(1):198-202. PMC: 124833. DOI: 10.1128/JCM.36.1.198-202.1998. View

20.

Walsh T, Melcher G, Rinaldi M, Lecciones J, McGough D, Kelly P . Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol. 1990; 28(7):1616-22. PMC: 267999. DOI: 10.1128/jcm.28.7.1616-1622.1990. View